Ocular Therapeutix, Inc. plans to file a New Drug Application for its AXPAXLI therapy for wet age-related macular degeneration by the end of this year.
The regulatory timeline is critical for the company as it seeks to establish a commercial moat in the retina market. By utilizing a specific FDA pathway, the company aims to shorten the time required for review and reach patients faster.
Ocular Therapeutix has scheduled a pre-NDA submission for the third quarter of 2026 [1]. Following that step, the company targets a full NDA filing in the fourth quarter of 2026 [2].
To accelerate the process, the company is using the 505(b)(2) regulatory pathway [2]. This specific route allows the company to rely on existing data for certain parts of the application, which may result in a 60-day reduction in the total FDA review time [3].
While some earlier projections suggested a timeline linked to data expected in early 2026, current plans focus on the late-year submission window. If the FDA approves the therapy following the Q4 filing, Ocular Therapeutix projects a commercial launch in 2027 [4].
The therapy targets wet age-related macular degeneration, a condition that causes vision loss. The company's strategy relies on the faster 505(b)(2) pathway to reduce the time between clinical trials, and market availability [5].
“Ocular Therapeutix targets a full NDA filing in the fourth quarter of 2026.”
The use of the 505(b)(2) pathway is a strategic move to bypass some of the more exhaustive requirements of a traditional New Drug Application. By leveraging existing data, Ocular Therapeutix reduces both the cost and time of development, potentially allowing them to capture market share in the competitive wet AMD space before rivals can iterate on their own delivery systems.
